R1 RCM (NASDAQ:RCM) Stock Rating Reaffirmed by Robert W. Baird

Robert W. Baird restated their outperform rating on shares of R1 RCM (NASDAQ:RCM) in a report published on Tuesday, Benzinga reports. The firm currently has a $18.00 price objective on the healthcare provider’s stock.

A number of other equities research analysts have also issued reports on RCM. Citigroup upgraded R1 RCM from a neutral rating to a buy rating and set a $16.00 price target for the company in a research note on Wednesday, March 20th. Cantor Fitzgerald restated an overweight rating and set a $20.00 price objective on shares of R1 RCM in a research report on Tuesday. Truist Financial restated a hold rating and set a $16.00 price objective on shares of R1 RCM in a research report on Monday, April 1st. Guggenheim cut their price objective on R1 RCM from $17.00 to $15.00 and set a buy rating for the company in a research report on Friday, April 5th. Finally, KeyCorp restated a sector weight rating on shares of R1 RCM in a research report on Wednesday, April 10th. Five research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of Moderate Buy and an average target price of $16.00.

R1 RCM Trading Down 13.2 %

Shares of RCM stock opened at $10.90 on Tuesday. R1 RCM has a 52-week low of $8.87 and a 52-week high of $18.70. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.79 and a current ratio of 1.79. The firm has a market capitalization of $4.59 billion, a PE ratio of -136.25 and a beta of 0.85. The stock has a fifty day simple moving average of $12.42 and a two-hundred day simple moving average of $11.90.

R1 RCM (NASDAQ:RCM) last issued its quarterly earnings results on Wednesday, May 8th. The healthcare provider reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03). R1 RCM had a negative return on equity of 1.16% and a negative net margin of 1.39%. The business had revenue of $603.90 million during the quarter, compared to analysts’ expectations of $612.88 million. The company’s revenue was up 10.7% on a year-over-year basis. On average, analysts predict that R1 RCM will post -0.17 EPS for the current fiscal year.

Institutional Trading of R1 RCM

Several institutional investors have recently added to or reduced their stakes in RCM. Voss Capital LLC lifted its stake in R1 RCM by 553.9% in the fourth quarter. Voss Capital LLC now owns 7,125,000 shares of the healthcare provider’s stock worth $75,311,000 after purchasing an additional 6,035,340 shares during the last quarter. Norges Bank bought a new stake in R1 RCM in the fourth quarter worth about $42,539,000. P2 Capital Partners LLC lifted its stake in R1 RCM by 70,366.3% in the fourth quarter. P2 Capital Partners LLC now owns 3,535,294 shares of the healthcare provider’s stock worth $37,368,000 after purchasing an additional 3,530,277 shares during the last quarter. Boston Partners lifted its stake in R1 RCM by 4,976.6% in the first quarter. Boston Partners now owns 2,570,371 shares of the healthcare provider’s stock worth $32,784,000 after purchasing an additional 2,519,739 shares during the last quarter. Finally, Sea Cliff Partners Management LP bought a new stake in R1 RCM in the fourth quarter worth about $18,459,000. Institutional investors own 61.10% of the company’s stock.

R1 RCM Company Profile

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.